| Assessment Status | Rapid Review Complete |
| HTA ID | 23019 |
| Drug | Fondaparinux |
| Brand | Arixtra® |
| Indication | Fondaparinux (Arixtra®) is indicated for the prevention of Venous Thromboembolic Events, treatment of Acute coronary syndrome, treatment of Superficial vein thrombosis, treatment of Deep vein thrombosis and acute Pulmonary Embolism. |
| Assessment Process | |
| Rapid review commissioned | 19/04/2023 |
| Rapid review resubmission required | 04/07/2023 |
| Rapid review completed | 28/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that fondaparinux not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. July 2024
